Curis

Curis Capital Intensity

The Capital Intensity Ratio of Curis (CRIS) as of Nov 20, 2026 is 211.44 %. In the previous year, Capital Intensity Ratio was 378.30 % — a change of -44.11% (lower).

Capital Intensity

211.44 %

YoY

-44.11%

Last updated:

Capital Intensity Ratio of Curis is 2025 211.44 % . Capital Intensity Ratio of Curis was 2024 378.30 % . It decreases by -44.11% lower compared to the previous year.

The Curis Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
358.31 USD
Jan 1, 2019
350.93 USD
Jan 1, 2020
1,886.09 USD
Jan 1, 2021
1,524.10 USD
Jan 1, 2022
1,071.13 USD
Jan 1, 2023
771.05 USD
Jan 1, 2024
378.30 USD
Jan 1, 2025
211.44 USD
The Curis Capital Intensity history
YEARCapital IntensityYoY
211.44 %-44.11%
378.30 %-50.94%
771.05 %-28.02%
1,071.13 %-29.72%
1,524.10 %-19.19%
1,886.09 %+437.46%
350.93 %-2.06%
358.31 %-51.94%
745.58 %-2.83%
767.26 %-36.35%
1,205.39 %+89.50%
636.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curis Stock analysis

What does Curis do? Curis Inc generates revenue primarily through the development and potential commercialization of its therapeutic drug candidates in the biotechnology sector. The company focuses on oncology treatments, with its lead candidate Emavusertib targeting IRAK4 kinase inhibition for cancer therapy. Other key products include Erivedge, which inhibits the Hedgehog signaling pathway, and additional candidates like CI-8993, Fimepinostat, CA-170, and CA-327, targeting various cancer-related pathways. The firm conducts R&D internally and via strategic collaborations, aiming to advance these drug candidates toward clinical and commercial stages. Curis Inc's primary buyers are pharmaceutical companies and healthcare institutions seeking innovative cancer treatments. The company's pipeline includes orally available small molecule drugs and monoclonal antibodies designed for targeted cancer therapies. Emavusertib, Erivedge, and CA-170 represent the core product segments, with CA-170 specifically targeting VISTA and PDL1 immune checkpoint proteins. Strategic collaborations support the development of these therapeutics, aligning with the company's focus on oncology drug discovery and development. The company's revenue streams are tied to the progression of its drug candidates through clinical trials and potential partnerships. Emavusertib and Erivedge are in clinical stages, with CA-170 also advancing in development. Curis Inc's business model emphasizes internal R&D alongside strategic alliances to accelerate the development of its pipeline, ensuring that its products reach the market for cancer treatment applications. Curis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curis stock

Capital Intensity Ratio of Curis is 211.44 % in 2025.

Capital Intensity Ratio of Curis changed from 378.30 % to 211.44 %, representing a -44.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Curis since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Curis with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Curis

All Key Metrics — Curis